uniQure(NASDAQ) QURE

Market Cap$2.49B

Since IPO (2014)+151%

5 Year+38%

1 Year+193%

1 Month-15%

$40.01

+9.14%

+3.35Today

uniQure last closing stock price
Metric	Price	Date
Last close	USD 40.07	2026-07-29

uniQure stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-0.77%	USD 40.38	2026-07-22
1 month	-15.45%	USD 47.39	2026-06-29
3 month	+100.85%	USD 19.95	2026-04-30
Year to date	+67.45%	USD 23.93	2025-12-31
1 year	+192.91%	USD 13.68	2025-07-29
3 year	+306.39%	USD 9.86	2023-07-28
5 year	+38.12%	USD 29.01	2021-07-30
Since inception	+150.92%	USD 14.61	2014-02-05

uniQure Financials at a Glance

Market Cap

$2.49B

Revenue (TTM)

$18.67M

Net Income (TTM)

-$252.21M

EPS (TTM)

-$3.51

P/E Ratio

-10.44

Dividend

$0.00

Beta (Volatility)

1.40 (Average)

Dividend

$0.00

Beta (Volatility)

1.40 (Average)

Price

$40.01

Volume

3,859,414.912

Open

$38.00

Price

$40.01

Volume

3,859,414.912

Open

$38.00

Previous Close

$40.07

Daily Range

$37.43 - $42.00

52-Week Range

$8.73 - $71.50

Estimated Earnings Date

Jul 29, 2026

Dividend

$0.00

Beta (Volatility)

1.40 (Average)

Price

$40.01

Volume

3,859,414.912

Open

$38.00

Previous Close

$40.07

Daily Range

$37.43 - $42.00

52-Week Range

$8.73 - $71.50

Estimated Earnings Date

Jul 29, 2026

QURE News

Page 1

QURE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About uniQure

uniQure N.V. is a leader in the field of gene therapy, committed to developing transformative treatments for patients with rare and severe diseases. The company's strategy focuses on delivering single treatments with potentially curative outcomes, addressing unmet medical needs.

Products and Services

HEMGENIX: A gene therapy for hemophilia B, approved by both the FDA and EMA.

AMT-130: A gene therapy candidate for Huntington's disease, currently in clinical trials.

AMT-162: An investigational gene therapy for ALS caused by SOD1 mutations.

AMT-191: A gene therapy candidate for the treatment of Fabry disease.

AMT-260: A gene therapy candidate targeting refractory mesial temporal lobe epilepsy.

What Makes uniQure N.V. Special

uniQure's proprietary gene therapy platform allows for the development of durable and precise therapeutic solutions. Their capability spans the entire gene therapy process from R&D to manufacturing, offering comprehensive solutions adaptable to various genetic disorders.

Five Things You Need to Know

uniQure has a partnership with CSL Behring for the commercialization of HEMGENIX, with specific royalty and milestone payments.

uniQure's manufacturing facility in Lexington, Massachusetts, is recognized for its advanced gene therapy production capabilities.

The company has received Orphan Drug and Fast Track designations for its Huntington's disease program (AMT-130) from the FDA.

A significant reorganization in late 2023 led to a focus on advancing their clinical-stage programs and resulted in a 20% workforce reduction.

uniQure entered a royalty purchase agreement in 2023, providing the company with $375 million in upfront cash for part of the HEMGENIX royalty stream.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

221

CEO

Matt Kapusta, MBA, CPA

Website

www.uniqure.com

Headquarters

Amsterdam, NH 1105 BP, NL

QURE Financials

Key Financial Metrics (TTM)

Gross Margin

76.59%

Operating Margin

-1069.34%

Net Income Margin

-1350.73%

Return on Equity

-111.96%

Return on Capital

-25.54%

Return on Assets

-25.60%

Earnings Yield

-9.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.49B

Shares Outstanding

68.01M

Volume

3.86M

Avg. Volume

2.19M

Financials (TTM)

Gross Profit

$14.30M

Operating Income

-$199.67M

EBITDA

-$163.27M

Operating Cash Flow

-$160.79M

Capital Expenditure

-$226.00K

Free Cash Flow

-$161.01M

Cash & ST Invst.

$810.34M

Total Debt

$62.83M

uniQure Performance Analysis

uniQure annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 106,483,000	-79.7%
2023	2023-12-31	USD 15,843,000	-85.1%
2024	2024-12-31	USD 27,119,000	71.2%
2025	2025-12-31	USD 16,098,000	-40.6%

uniQure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-29.7%
Q4	2025-12-31	50.4%
Q1	2026-03-31	-36.0%
Q2	2026-06-30	64.0%

uniQure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.71	N/A
2023	2023-12-31	USD -6.47	138.5%
2024	2024-12-31	USD -4.92	-23.9%
2025	2025-12-31	USD -3.46	-29.7%

uniQure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-100.0%
Q4	2025-12-31	57.2%
Q1	2026-03-31	-44.1%
Q2	2026-06-30	-43.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$5.84M

+11.0%

Gross Profit

$5.49M

+19.2%

Gross Margin

94.01%

N/A

Market Cap

$2.49B

N/A

Market Cap/Employee

$11.28M

N/A

Employees

221

N/A

Net Income

-$81.06M

-114.9%

EBITDA

-$52.20M

-188.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$810.34M

+115.0%

Total Debt

$62.83M

-5.8%

Accounts Receivable

$13.69M

+144.2%

Inventory

$0.00

N/A

Long Term Debt

$69.54M

+10.8%

Short Term Debt

$5.98M

+53.0%

Return on Assets

-25.60%

N/A

Return on Invested Capital

-22.14%

N/A

Free Cash Flow

-$29.05M

+27.7%

Operating Cash Flow

-$28.58M

+28.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CLDXCelldex Therapeutics, Inc.

CLDXCelldex Therapeutics, Inc.$37.51+5.42%

VERAVera Therapeutics, Inc.

VERAVera Therapeutics, Inc.$32.51-2.43%

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$6.59-1.49%

GPCRStructure Therapeutics Inc.

GPCRStructure Therapeutics Inc.$47.35-1.13%

GLPGGalapagos N.V.

GLPGGalapagos N.V.$27.98+1.71%

MESOMesoblast Limited

MESOMesoblast Limited$14.13-2.21%

OCULOcular Therapeutix, Inc.

OCULOcular Therapeutix, Inc.$8.36-1.07%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.25-0.09%

INTCIntel

INTCIntel$81.88-0.05%

NVDANvidia

NVDANvidia$190.01-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

FFord Motor Company

FFord Motor Company$15.28+0.02%

NOKNokia

NOKNokia$8.41-0.06%

JBLUJetBlue Airways

JBLUJetBlue Airways$5.72-0.05%

Questions About QURE

What is the current price of uniQure?

uniQure is trading at $40.07 per share.

What is the 52-week range for uniQure?

Over the past 52 weeks, uniQure has traded between $8.73 and $71.50.

How much debt does uniQure have?

As of the most recent reporting period, uniQure reported total debt of $545.66M.

How much cash does uniQure have on hand?

uniQure reported $139.99M in cash and cash equivalents in its most recent financial results.

What is uniQure’s dividend yield?

uniQure does not currently have a dividend yield.

uniQure(NASDAQ) QURE

uniQure Financials at a Glance

QURE News

uniQure Narrows Loss in Fiscal Q2

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Why Shares of uniQure Are Up Thursday

Why Shares of uniQure Are Dropping Tuesday

Why uniQure Stock Cratered This Week

Why uniQure Stock Is Crashing Today

Why Shares of uniQure Rose 14.61% on Wednesday

Why uniQure Stock Is Crashing Today

QURE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About uniQure

Products and Services

What Makes uniQure N.V. Special

Five Things You Need to Know

QURE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

uniQure Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About QURE

What is the current price of uniQure?

What is the 52-week range for uniQure?

How much debt does uniQure have?

How much cash does uniQure have on hand?

What is uniQure’s dividend yield?

Premium Investing Services